Koers Guardion Health Sciences Inc Nasdaq
Aandelen
US40145Q2030
Farmaceutische producten
Omzet 2022 | 11,05 mln. 10,3 mln. | Omzet 2023 | 12,25 mln. 11,41 mln. | Marktkapitalisatie | 6,81 mln. 6,34 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -14 mln. -13,04 mln. | Nettowinst (verlies) 2023 | - 0 | EV/omzet 2022 | -0,16 x |
Nettoliquiditeiten 2022 | 10,65 mln. 9,92 mln. | Nettoliquiditeiten 2023 | 6,36 mln. 5,93 mln. | EV/omzet 2023 | 0,04 x |
K/w-verhouding 2022 |
-0,51
x | K/w-verhouding 2023 |
42,9
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 79,71% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jan Hall
CEO | Chief Executive Officer | - | 19-06-23 |
Chairman | 72 | 30-06-15 | |
Katie Cox
AUD | Comptroller/Controller/Auditor | - | 25-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 72 | 30-06-15 | |
Mark Goldstone
BRD | Director/Board Member | 60 | 01-06-15 |
Donald Gagliano
BRD | Director/Board Member | 71 | 09-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,82% | 791 mld. | |
+40,45% | 630 mld. | |
+16,95% | 328 mld. | |
+9,49% | 298 mld. | |
+17,25% | 246 mld. | |
+0,41% | 225 mld. | |
+10,22% | 218 mld. | |
+5,30% | 160 mld. | |
-6,29% | 156 mld. |